1. Home
  2. JYNT vs LCTX Comparison

JYNT vs LCTX Comparison

Compare JYNT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JYNT
  • LCTX
  • Stock Information
  • Founded
  • JYNT 2010
  • LCTX 1990
  • Country
  • JYNT United States
  • LCTX United States
  • Employees
  • JYNT N/A
  • LCTX N/A
  • Industry
  • JYNT Multi-Sector Companies
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JYNT Miscellaneous
  • LCTX Health Care
  • Exchange
  • JYNT Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • JYNT 163.0M
  • LCTX 165.6M
  • IPO Year
  • JYNT 2014
  • LCTX N/A
  • Fundamental
  • Price
  • JYNT $11.70
  • LCTX $0.89
  • Analyst Decision
  • JYNT Strong Buy
  • LCTX Strong Buy
  • Analyst Count
  • JYNT 2
  • LCTX 3
  • Target Price
  • JYNT $18.00
  • LCTX $5.67
  • AVG Volume (30 Days)
  • JYNT 46.8K
  • LCTX 327.9K
  • Earning Date
  • JYNT 11-07-2024
  • LCTX 11-07-2024
  • Dividend Yield
  • JYNT N/A
  • LCTX N/A
  • EPS Growth
  • JYNT N/A
  • LCTX N/A
  • EPS
  • JYNT N/A
  • LCTX N/A
  • Revenue
  • JYNT $120,071,078.00
  • LCTX $6,186,000.00
  • Revenue This Year
  • JYNT $0.70
  • LCTX N/A
  • Revenue Next Year
  • JYNT N/A
  • LCTX $119.00
  • P/E Ratio
  • JYNT N/A
  • LCTX N/A
  • Revenue Growth
  • JYNT 7.46
  • LCTX N/A
  • 52 Week Low
  • JYNT $7.31
  • LCTX $0.77
  • 52 Week High
  • JYNT $17.82
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • JYNT 51.57
  • LCTX 48.24
  • Support Level
  • JYNT $10.80
  • LCTX $0.83
  • Resistance Level
  • JYNT $12.02
  • LCTX $0.94
  • Average True Range (ATR)
  • JYNT 0.40
  • LCTX 0.05
  • MACD
  • JYNT 0.14
  • LCTX 0.00
  • Stochastic Oscillator
  • JYNT 81.10
  • LCTX 41.92

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: